PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Abatacept - Rheumatoid arthritis

PAD Profile : Abatacept - Rheumatoid arthritis Important

Keywords :
RA, Biologic, NICE, immunosuppressant, T-cell co-stimulation inhibitor, DMARD, Bdmard, Disease modulating, Rheumatology
Brand Names Include :
Orencia
Important Information :
Severe disease only. NON-FORMULARY for moderate disease

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathways (moderate and severe).

01 September 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Abatacept is NON-FORMULARY for moderate disease.

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agrees with the recommendations made in NICE TA715.

Abatacept for moderately active Rheumatoid Arthritis was not recommended by NICE and will be given a NON-FORMULARY traffic light status for this indication. The current treatment pathway is attached below.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More